Skip to content

Home
Team
Portfolio
News
- TCG News
- Portfolio News
Careers
Contact

Menu

Home
Team
Portfolio
News
- TCG News
- Portfolio News
Careers
Contact

November 2021

eFFECTOR Therapeutics Announces Publication of Zotatifin Preclinical Data in Frontiers in Oncology

Portfolio News / By Karina Tin

November 24, 2021

Surrozen Presents Data Supporting Potential of SZN-043 at The Liver Meeting 2021, the Annual Meeting of the American Association for the Study of Liver Diseases

Portfolio News / By Karina Tin

November 15, 2021

Surrozen Reports Third Quarter 2021 Financial Results

Portfolio News / By Karina Tin

November 15, 2021

Nurix Therapeutics Presents Beneficial Effects of CBL-B Inhibition on Human Tumor Infiltrating Lymphocytes at SITC Conference

Portfolio News / By Karina Tin

November 12, 2021

Nurix Therapeutics Announces IND clearance for DeTIL-0255, a drug-enhanced autologous T cell therapy for the potential treatment of a variety of solid tumors

Portfolio News / By Karina Tin

November 12, 2021

A2 Bio Provides First Preclinical Data Presentation for CEA and MSLN Programs, Including Trial Update at SITC 2021

Portfolio News / By Karina Tin

November 12, 2021

RAPT Therapeutics Reports Third Quarter 2021 Financial Results

Portfolio News / By Karina Tin

November 10, 2021

Tenaya Therapeutics Reports Third Quarter 2021 Financial Results and Provides Business Updates

Portfolio News / By Karina Tin

November 10, 2021

Revolution Medicines Reports Third Quarter Financial Results and Update on Corporate Progress

Portfolio News / By Karina Tin

November 10, 2021

eFFECTOR Therapeutics Reports Third Quarter 2021 Financial Results and Provides Corporate Update

Portfolio News / By Karina Tin

November 8, 2021

Posts navigation

1 2 Next Page →

Search for:

Recent Posts

Revolution Medicines Announces Commencement of Public Offering of Common Stock
NGM Bio Provides Business Highlights and Reports Fourth Quarter and Full Year 2022 Financial Results
Revolution Medicines Reports Fourth Quarter and Full Year 2022 Financial Results and Update on Corporate Progress
eFFECTOR Therapeutics Announces Positive Top-Line Results from Phase 1b Clinical Trial of Zotatifin for the Treatment of COVID
Neurona Therapeutics Announces FDA Clearance of Expanded Inclusion Criteria for Phase I/II Clinical Trial of NRTX-1001 Regenerative Cell Therapy in Patients with Dominant Hemisphere Drug-Resistant Focal Epilepsy

Recent Comments

Archives

Categories

Portfolio News
TCG News

The Column Group

Copyright © 2022. The Column Group | Privacy Policy | Terms of Use
Website developed by CP Communications

Scroll to Top